仑伐替尼联合信迪利单抗对晚期肝癌患者肿瘤标志物水平及生存情况的影响

doi:10.3969/j.issn.1001-8131.2025.02.002

摘要
图/表
参考文献
相关文章 (6)

全文: PDF (570 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨仑伐替尼联合信迪利单抗对晚期肝癌患者肿瘤标志物水平及生存情况的影响。方法回顾性收集96例晚期肝癌患者资料,按不同治疗方案分为对照组（48例）、研究组（48例）;对照组予仑伐替尼治疗,研究组予仑伐替尼联合信迪利单抗治疗,均至少治疗3个周期;统计并对比两组的治疗效果、肿瘤标志物水平、肝功能指标、生存质量、不良反应及生存情况。结果研究组疾病控制率较对照组高（P<0.05）;研究组治疗3个周期,甲胎蛋白（AFP）、癌胚抗原（CEA）、异常凝血酶原（PIVKA-Ⅱ）、糖类抗原（CA199）、总胆红素（TBIL）、谷草转氨酶（AST）、丙氨酸氨基转移酶（ALT）水平较对照组低;研究组治疗3个周期癌症患者生命质量测定量表（EORTC QLQ-C30）各维度评分较对照组高（P<0.05）;研究组不良反应与对照组对比,差异无统计学意义（P>0.05）;研究组存活率较对照组高（P<0.05）。结论仑伐替尼联合信迪利单抗治疗晚期肝癌患者效果较好,可降低肿瘤标志物水平,减轻肝功能损伤,改善生存质量,提高生存率,且安全性好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周国辉

关键词 ：晚期肝癌, 仑伐替尼, 信迪利单抗, 肿瘤标志物, 生存情况

Abstract：Objective To investigate the effects of lenvatinib combined with sintilimab on tumor marker levels and survival in patients with advanced liver cancer.Method A retrospective collection of data was conducted on 96 patients with advanced liver cancer.They were divided into a control group（48 cases）and a study group（48 cases）according to different treatment plans;The control group was treated with lenvatinib,while the study group was treated with lenvatinib combined with sildenafil monoclonal antibody for at least 3 cycles;Compare and analyze the treatment efficacy,tumor marker levels,liver function indicators,quality of life,adverse reactions,and survival status between the two groups.The disease control rate of the research group（70.83%）was higher than that of the control group（41.67%）（P<0.05）;The research group had lower levels of alpha fetoprotein（AFP）,carcinoembryonic antigen（CEA）,abnormal prothrombin（PIVKA II）,carbohydrate antigen（CA199）,total bilirubin（TBIL）,aspartate aminotransferase（AST）,and alanine aminotransferase（ALT）compared to the control group after three cycles of treatment;The study group had higher scores in all dimensions of the EORTC QLQ-C30 quality of life assessment scale for cancer patients treated for three cycles compared to the control group（P<0.05）;There was no statistically significant difference in adverse reactions between the study group（14.58%）and the control group（10.42%）（P>0.05）;The survival rate of the study group was higher than that of the control group,and the median survival time was longer than that of group A（P<0.05）.Conclusion The combination of lenvatinib and xindilimab is effective in the treatment of advanced liver cancer patients,reducing tumor marker levels,alleviating liver function damage,improving quality of life,and increasing survival rate,with good safety.

Key words： Advanced liver cancer Lenvatinib Xindilimumab Tumor markers Survival situation

收稿日期: 2025-02-20

PACS:

R735.7

引用本文:

周国辉. 仑伐替尼联合信迪利单抗对晚期肝癌患者肿瘤标志物水平及生存情况的影响[J]. 哈尔滨医药, 2025, 45(2): 4-4.
Zhou Guohui. The Effect of Lenvatinib Combined with Xindilimab on Tumor Marker Levels and Survival in Patients with Advanced Liver Cancer. journal1, 2025, 45(2): 4-4.

链接本文:

http://www.hrbyybjb.org.cn/CN/10.3969/j.issn.1001-8131.2025.02.002 或 http://www.hrbyybjb.org.cn/CN/Y2025/V45/I2/4

[1] Wang W,Lu K,Jiang X,et al.Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer[J].J Exp Clin Cancer Res,2023,42(1):142.
[2] Yang X,Wang J,Wang H.Association between sleep traits and primary liver cancer:A Mendelian randomization analysis[J].Eur J Clin Invest,2023,53(8):e14002.
[3] Wang J,Yu H,Dong W,et al.N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/beta-Catenin and Hippo Signaling Pathways[J].Gastroenterology,2023,164(6):990-1005.
[4] 徐彬,李小龙,朱小东,等.在接受仑伐替尼联合PD-1抗体治疗的不可切除肝细胞癌患者肝切除术前行门静脉栓塞术的研究[J].中华肝胆外科杂志,2022,28(1):21-27.
[5] 黎旺红,唐津天,易超,等.信迪利单抗,仑伐替尼联合TACE成功转化巨大肝细胞癌一例[J].肝胆胰外科杂志,2024,36(5):294-296,301.
[6] 卢芳,施尧,张晨曦,等.信迪利单抗治疗晚期肝癌的有效性及安全性分析[J].医学研究生学报,2023,36(8):852-855.
[7] 中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2022年版)[J].中华消化外科杂志,2022,21(9):1137-1164.
[8] Watanabe H,Okada M,Kaji Y,et al.New response evaluation criteria in solid Tumours-Revised RECIST Guideline (Version 1.1)[J].Gan To Kagaku Ryoho,2009,36(13):2495-2501.
[9] 王岩,朱琳,陈鹏.肿瘤患者生命质量测定量表EORT CQLQ-C30维文版评价[J].中国卫生统计,2015,32(3):512-513.
[10] Huang DQ,Singal AG,Kono Y,et al.Changing global epidemiology of liver cancer from 2010 to 2019:NASH is the fastest growing cause of liver cancer[J].Cell Metab,2022,34(7):969-977.
[11] Huang M,Long J,Yao Z,et al.METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma[J].Cancer Res,2023,83(1):89-102.
[12] Pan J,Zhang M,Dong L,et al.Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma[J].Autophagy,2023,19(4):1184-1198.
[13] 费睿成,亓民.PD-1单抗联合TACE对晚期原发性肝癌患者的治疗效果[J].实用中西医结合临床,2024,24(10):16-19.
[14] 陈秋平,邵明义,张容容,等.信迪利单抗联合化疗方案一线治疗晚期,复发或转移性食管鳞状细胞癌的成本-效用分析[J].中国药房,2023,34(3):345-349.
[15] 叶小荣,程涛,易弼顺.信迪利单抗联合XELIRI方案治疗结直肠癌的疗效及预后影响因素[J].中国药物与临床,2024,24(16):1068-1072.
[16] 王勇军,王志英,王红英,等.信迪利单抗联合仑伐替尼治疗中晚期肝癌临床观察[J].肿瘤基础与临床,2024,37(5):514-517.